Picture loading failed.

Anti-CD52 therapeutic antibody (Pre-made Alemtuzumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis. In CLL, it has been used as both a first line and second line treatment. In MS it is generally only recommended if other treatments have not worked. It is given by injection into a vein.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-015-1mg 1mg 3090
GMP-Bios-ab-015-10mg 10mg 21890
GMP-Bios-ab-015-100mg 100mg 148000
GMP-Bios-ab-015-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD52 therapeutic antibody (Pre-made Alemtuzumab biosimilar,Whole mAb)
INN Name Alemtuzumab
TargetCD52
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI Structure1bey:HL/1ce1:HL
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2000
Year Recommended2001
CompaniesBayer HealthCare Pharmaceuticals Inc.;Dana-Farber Cancer Institute;German CLL Study Group;Ohio State University Comprehensive Cancer Center;Sanofi;Sanofi Oncology;University of Cologne;University of Cambridge
Conditions ApprovedChronic lymphocytic leukaemia;Multiple sclerosis
Conditions ActiveLymphoma;T-cell prolymphocytic leukaemia
Conditions DiscontinuedRheumatoid arthritis;Diffuse large B cell lymphoma;Graft-versus-host disease;Sezary syndrome;T-cell lymphoma
Development Techna